GKOS vs SGHT
GKOS: Glaukos is a specialized ophthalmic company transforming eye care through innovative Micro-Invasive Glaucoma Surgery devices and proprietary sustained-release pharmaceutical therapies. SGHT: Sight Sciences develops minimally invasive interventional devices for glaucoma and dry eye, targeting ophthalmology markets through reimbursement-focused commercialization.
Side-by-side fundamentals
| Metric | GKOS | SGHT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $152.86 | $5.03 | |
| Market cap as of 2026-07-23 | $8.9B | $274M | |
| PEG as of 2026-07-23 | -1.09 | n/a | |
| Net margin as of 2026-07-23 | -34.3% | -46.8% | GKOS higher |
| Gross margin as of 2026-07-23 | +78.1% | +86.9% | SGHT higher |
| Operating margin as of 2026-07-23 | -36.0% | -44.8% | GKOS higher |
| ROE as of 2026-07-23 | -26.5% | -59.1% | GKOS higher |
| ROA as of 2026-07-23 | -20.1% | -32.2% | GKOS higher |
| Debt / equity as of 2026-07-23 | 0.10 | 0.75 | GKOS lower |
| Revenue growth (YoY) as of 2026-07-23 | +36.3% | +1.9% | GKOS higher |
| Revenue CAGR (3y) SEC XBRL | +21.5% | +2.7% | GKOS higher |
| Beta as of 2026-07-23 | 0.75 | 2.47 | |
| 1-year return as of 2026-07-22 close | +58.3% | +43.1% | GKOS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.